Cited by 38Mast cells and histamineCongenital gastrointestinal and neural anomaliesPlatelet Disorders and Treatments

Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

Open access
González‐de‐Olano, David, Navarro‐Navarro, Paula, Muñoz‐González, Javier I., Sánchez‐Muñoz, Laura, Henriques, Ana, de‐Andrés‐Martín, Ana, Peralta‐Arjonilla, Dolores, Mayado, Andrea +4 more·2024·Allergy

Abstract

Background: A close association between hereditary alpha‐tryptasemia (HAT) and mast cell (MC) disorders has been previously reported. However, the relationship between HAT and the diagnostic subtypes and clinical features of MC disorders still remains to be established. Objective: To determine the prevalence of HAT in healthy donors (HD) vs patients with different diagnostic subtypes of MC activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease. Methods: A total of 959 subjects were studied including 346 healthy donors (HD), 464 mastocytosis, and 149 non‐clonal MCAS patients. Molecular studies to assess the TPSAB1 genotype were performed, and data on serum baseline tryptase (sBT) and basal MC‐mediator release episodes and triggers of anaphylaxis were collected. Results: HAT was detected in 15/346 (4%) HD versus 43/149 (29%) non‐clonal MCAS and 84/464 (18%) mastocytosis cases. Among mastocytosis, HAT was more frequently found in patients with MC‐restricted KITD816V (21% vs. 10% among multilineage KITD816V patients; p = .008). Overall, median sBT was higher in cases presenting with HAT (28.9 vs. 24.5 ng/mL; p = .008), while no significant differences in sBT were observed among HAT+ mastocytosis patients depending on the presence of 1 vs. ≥2 extra copies of the α‐tryptase gene (44.1 vs. 35.2 ng/mL, p > .05). In turn, anaphylaxis was more frequently observed in HAT+ versus HAT− mastocytosis patients (76% vs. 65%; p = .018), while HAT+ and HAT− patients who did not refer anaphylaxis as the presenting symptom (n = 308) showed a similar prevalence of subsequent anaphylaxis (35% vs. 36%, respectively). Conclusion: The frequency of HAT in MC disorders varies according to the diagnostic subtype of the disease. HAT does not imply a higher risk (and severity) of anaphylaxis in mastocytosis patients in whom anaphylaxis is not part of the presenting symptoms of the disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/all.15911

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent study did not find a difference in the prevalence of HαT in patients with or without anaphylaxis with underlying systemic mastocytosis.

    “However, a recent study did not find a difference in the prevalence of HαT in patients with or without anaphylaxis with underlying SM [54], and more studies with opposing results exist [55].”

    From Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders (2023) · cites this paper as [54]

    Section 3.1 reports no statistically significant difference in HαT prevalence between mastocytosis patients with and without concomitant MCAS (20% vs. 15%), and the Discussion says an increased anaphylaxis risk could not be confirmed among mastocytosis cases. However, MCAS is not identical to anaphylaxis, and the paper also reports more anaphylaxis among HαT-positive than HαT-negative mastocytosis patients (76% vs. 65%; p = .018). The unqualified claim therefore misses a conflicting result in the source. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Arber DA, Orazi A, Hasserjian RP, et al. International consen- sus classification of myeloid neoplasms and acute Leukemias- integratingmorphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228.
  2. Hoermann G, Gleixner KV, Dinu GE, et al. The KIT D816V allele bur- den predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014;69(6):810-813.

Cited by

Sorted by citations

Authors
González‐de‐Olano, D., Navarro‐Navarro, P., Muñoz‐González, J. I., Sánchez‐Muñoz, L., Henriques, A., de‐Andrés‐Martín, A., Peralta‐Arjonilla, D., Mayado, A., Jara‐Acevedo, M., García‐Montero, A. C., Orfao, A., & Álvarez‐Twose, I.
Affiliations
  • Instituto Ramón y Cajal de Investigación Sanitaria (ES)
  • Universidad de Salamanca (ES)
  • Centro de Investigación Biomédica en Red de Cáncer (ES)
  • Hospital Virgen del Valle (ES)
  • Instituto de Investigación Biomédica de Salamanca (ES)
  • Spanish Network on Mastocytosis (REMA), Toledo and Salamanca Salamanca Spain
Venue
Allergy
Publisher
Wiley
Published
2023-10-11
Volume
79
Issue
3
Pages
711-723
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W4387563545
Cited by
38
References
45
Citations by year
2026: 11 · 2025: 13 · 2024: 12 · 2023: 2
FWCI
4.17
Type
journal article
Language
en
Open access
Locations
  • Allergy (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders
Instituto de Salud Carlos III
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
hereditary alpha-tryptasemia, mast cell activation syndrome, mastocytosis, KIT D816V mutation, serum tryptase, anaphylaxis, mast cell mediators, disease severity, healthy donors
MeSH terms
Mast Cell Activation Syndrome, Anaphylaxis, Genotype, Humans, Mast Cells, Mastocytosis, Tryptases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review